Jack Hadfield: An Important Step Toward Finding Measurable Biology in Long COVID
Jack Hadfield, Co-founder and Research Lead at Amatica Health, shared a post on LinkedIn about a recent article by Asghar Abbasi et al, published in Infection:
”Pieces of SARS-CoV-2 proteins were found in tiny blood particles in people with long COVID, even many months after infection.
These particles are called extracellular vesicles, or EVs. EVs are small packages released by cells into the blood that can carry proteins and other biological material.
In this study, researchers looked at 14 adults with long COVID symptoms including fatigue, shortness of breath, exercise intolerance, and post-exertional malaise. On average, they were studied about 17 months after infection.
The team isolated EVs from blood samples and used mass spectrometry, a lab method that identifies molecules by their molecular pattern, to look for pieces of SARS-CoV-2 proteins.
They detected 65 viral protein fragments linked to a viral protein called Pp1ab in 22 of 56 samples. The authors also reported that each participant had at least one SARS-CoV-2 peptide detected in EVs at some point across the sampling period.
They then used a more targeted confirmation method and verified one specific viral peptide in 12 of the 14 participants across multiple time points. None of the 20 pre-pandemic control samples showed the same signal.
This does not prove live virus is still present. It does not prove these protein fragments are causing symptoms. And it does not establish a clinical test.
But it may point to an ongoing biological signal in at least some people with long COVID, and that is why this paper is worth paying attention to.
The main caveats are also important. This was a very small study. It was a short correspondence paper, not a large validation study. The signal was not found in every sample, and the study did not include a key comparison group of people who had COVID and recovered without long COVID.
So the balanced takeaway is this: early evidence, not proof, but a potentially important step toward finding measurable biology in long COVID.
The details above come directly from the paper’s cohort description, EV proteomics methods, peptide findings, targeted validation, and control comparisons”
Title: Possible long COVID biomarker: identification of SARS-CoV-2 related protein(s) in Serum Extracellular Vesicles
Authors: Asghar Abbasi, Ritin Sharma, Nathaniel Hansen, Patrick Pirrotte, William W. Stringer
Read the Full Article on Infection
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 13, 2026, 10:00Mandy Lauw: Can Reduced-Dose DOACs Be Applied to All Patients With VTE?
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol